To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC11526 | Praliciguat Featured |
Praliciguat (IW-1973, IW1973) is a potent, orally available sGC stimulator that concentration-dependently increases the production of cGMP with EC50 of 267 nM.
More description
|
|
| DC7280 | Pracinostat(SB939) Featured |
Pracinostat(SB939) is a potent pan-HDAC inhibitor with IC50 of 40-140 nM with exception for HDAC6; has no activity against the class III isoenzyme SIRT I.
More description
|
|
| DC7252 | PR-619 Featured |
PR-619 is a broad-range DUB inhibitor with potential for further development as a chemotherapeutic agent in cancer therapy.
More description
|
|
| DC7483 | PPQ-102 Featured |
PPQ-102 is a potent CFTR inhibitor which can completely inhibited CFTR chloride current with IC 50approximately 90 nM.
More description
|
|
| DC7482 | Torkinib (PP242) Featured |
PP242 is a selective mTOR inhibitor with IC50 of 8 nM; targets both mTOR complexes with >10- and 100-fold selectivity for mTOR than PI3Kδ or PI3Kα/β/γ, respectively; also showed slightly weaker activity against BRD4 (Kd= 1.7 uM).
More description
|
|
| DC5008 | PP2(AGL 1879) Featured |
PP2 is Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
More description
|
|
| DC9931 | PP2 analog Featured |
PP2 analog is the analog of PP2,a Src family kinase inhibitor.
More description
|
|
| DC5007 | pp1 Featured |
PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
More description
|
|
| DC7704 | Poziotinib Featured |
Poziotinib, is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.
More description
|
|
| DC7251 | AM 281 Featured |
Potent, selective CB1 cannabinoid receptor antagonist/inverse agonist (Ki values are 12 and 4200 nM for CB1 and CB2 receptors respectively). Increases locomotor activity following systemic administration in vivo. Analog of SR141716A (Ki = 14 nM).
More description
|
|
| DC7574 | FIPI Featured |
Potent phosholipase D (PLD) inhibitor (IC50 values are 20 and 25 nM for PLD2 and PLD1 respectively).
More description
|
|
| DC8022 | R-268712 Featured |
Potent and selective inhibitor of the TGF-β type I receptor/ALK5 (IC50 = 2.5 nM). Exhibits ~ 5000-fold selectivity over p38 MAPK. Suppresses development of renal fibrosis in a unilateral ureteral obstruction model. Also reduces proteinuria, glomeruloscler
More description
|
|
| DC9742 | Ponesimod Featured |
Ponesimod(ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator with EC50 of 5.7 nM.
More description
|
|
| DC7588 | PNU120596 Featured |
PNU-120596 is a positive allosteric modulator of α7 nAChR with EC50 of 216 nM.
More description
|
|
| DC7241 | PND-1186 Featured |
PND-1186 is a potent FAK inhibitor with IC50 of 1.5 nM.
More description
|
|
| DC6301 | PLX-4720 Featured |
PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
More description
|
|
| DC1071 | Vemurafenib (PLX4032) Featured |
PLX4032 (Vemurafenib, RG7204, Zelboraf, RO5185426) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM.
More description
|
|
| DC8158 | Pexidartinib(PLX3397) Featured |
PLX3397 is a tyrosine kinase inhibitor that potently inhibits the colony stimulating factor 1 (CSF1) receptor kinase, a driving force in the development and growth of PVNS.
More description
|
|
| DC7239 | PluriSln 1(NSC 14613) Featured |
PluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.
More description
|
|
| DC8749 | Plinabulin Featured |
Plinabulin (NPI-2358) is a vascular disrupting agents (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells.
More description
|
|
| DC8741 | Plerixafor octahydrochloride Featured |
Plerixafor octahydrochloride(AMD3100 8HCL) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively.
More description
|
|
| DC7238 | Gedatolisib(PKI-587) Featured |
PKI-587 is a highly potent dual PI3K/mTOR kinase inhibitor with IC50 of 0.4 nM and <0.1 μM for PI3K-α and mTOR, respectively.
More description
|
|
| DC10821 | PKG drug G1 Featured |
PKG drug G1 has been shown to induce the oxidative activation of protein kinase G Iα, which in vivo results in dilation of blood vessel and blood pressure lowering; an antihypertensive.
More description
|
|
| DC7634 | PKC-412 (Midostaurin) Featured |
PKC-412 is a broad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms (α, β, γ), PDFRβ, VEGFR2, Syk, PKCη, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity.
More description
|
|
| DC7237 | PJ34 HCl Featured |
PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.
More description
|
|
| DC21940 | Pizuglanstat Featured |
Pizuglanstat is a potent, selective prostaglandin D synthase inhibitor..
More description
|
|
| DC9465 | Pitolisant (hydrochloride) Featured |
Pitolisant Hcl(BF2.649;Ciproxidine ) is a novel, potent, and selective nonimidazole inverse agonist at the recombinant human H3 receptor (Ki=0.16 nM).
More description
|
|
| DC10012 | Pirmenol hydrochloride Featured |
Pirmenol hydrochloride inhibits IK.ACh by blocking muscarinic receptors. The IC50 of Pirmenol for inhibition of Carbachol-induced IK.ACh is 0.1 μM.
More description
|
|
| DC8792 | Pirfenidone(AMR69) Featured |
Pirfenidone(AMR69) is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Phase 3.
More description
|
|
| DCAPI1533 | Piperaquine Phosphate |
Piperaquine Phosphate
More description
|
|